cerrar
Tagged with Pricing

EUnetHTA 21 Launches Joint Scientific Consultations for…
Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA…

2021 Drug Formulary Exclusions Continue to Reduce Therapy Choice…
Susan L. Lang outlines how pharma companies can navigate drug formulary exclusions, numbers of which have been rising in recent years, and ensure that…

Flemming Sonne – CEO, Amgros, Denmark
Flemming Sonne of Denmark’s public hospital medicine procurement body Amgros outlines the scope and mission of the group, how its remit has…

USA: Drug Innovations Are Delivering for Patients; We Need…
John M. O’Brien, recently appointed president and CEO of the US National Pharmaceutical Council, calls for innovation in benefit design reform to…

Health Technology Assessment in the EU: Back and Forth in Giant…
Writing in the August edition of DIA's Global Forum, Sanofi R&D's Thomas Kühler outlines the bumpy journey towards the full adoption of Health…

Italy’s Market Access Reform: A Watershed Moment?
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical industry as the most significant…

How Pricing is Straining Turkish Pharma’s Sustainability
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over…

Switzerland’s Upcoming Cost Containment Packages: Industry…
While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland…

Five Ways That AI Can Transform Pharma Market Access
Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical…

China’s National Reimbursement Drug List (NRDL) 2020: What…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has…

China: New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s…

Navigating the Increasingly Stormy Waters of US Market Access 
Certara's Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here